FibroBiologics Inc. (FBLG) vs IMMURON (IMRN)

FibroBiologics Inc. and IMMURON are both Biotechnology companies. FibroBiologics Inc. and IMMURON are of similar size ($9.6M and $9.1M). FibroBiologics Inc. has the higher net margin (0.00% vs −262.7%) and the lower return on invested capital (−932.7% vs 0.00%). Across the 9 metrics below, IMMURON leads on 7 and FibroBiologics Inc. on 2.

Valuation

Metric FBLG IMRN Biotechnology median
P/E n/m n/m 7.88
P/S n/m n/m 11.47
P/B 1.88 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.93 0.74
EV/Sales n/m (3.50) 10.73
Earnings yield (373.38%) (1.75%) (28.84%)
Free cash flow yield (172.63%) 0.00% (23.03%)

Profitability

Metric FBLG IMRN Biotechnology median
Gross margin — 71.28% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% (262.71%) 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (660.08%) 0.00% (57.72%)
Return on assets (166.14%) 0.00% (49.22%)
Return on invested capital (932.71%) 0.00% 0.00%

Growth

Metric FBLG IMRN Biotechnology median
Revenue growth (TTM) — (6.62%) 5.64%
EPS growth (last fiscal year) (23.53%) 37.29% —
Revenue growth, 5-year CAGR — 116.96% 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric FBLG IMRN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.64 7.17 4.73
Net debt to EBITDA 0.31 2.25 0.96

Dividend

Metric FBLG IMRN Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric FBLG IMRN Biotechnology median
Market cap 9.06m 9.60m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack